Soligenix Inc Dossier
Qualitative Analysis
Business overview
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two primary business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment focuses on oncology and immune-mediated skin diseases, utilizing synthetic hypericin-based photodynamic therapy (such as SGX302 for psoriasis) and innate defense regulator (IDR) technology (such as SGX945 for Behu0007et's Disease). The Public Health Solutions segment develops biodefense and infectious disease vaccines, including RiVax (a ricin toxin vaccine candidate) and filovirus vaccine programs, leveraging its proprietary ThermoVax heat-stabilization platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Actively exploring strategic alternatives, which may include an acquisition, merger, business combination, or other transaction.
Expected impact: Aims to identify a transaction or path forward that maximizes value for shareholders.
Advancing the development of SGX945 (dusquetide) for Behçet's Disease, focusing on reformulating the drug from an intravenous formulation to a subcutaneous injection to enable home-based treatment.
Expected impact: Enables home-use administration and positions the asset for a follow-on placebo-controlled Phase 2b clinical trial.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Completed the transfer of the manufacturing process for synthetic hypericin to Sterling Pharma Solutions to establish a scalable production process under cGMP requirements.
Terms: Not explicitly disclosed; intended to establish a long-term commercial manufacturing collaboration.